Merbentul - General Information
A powerful synthetic, non-steroidal estrogen. [PubChem]
Pharmacology of Merbentul
Merbentul is a nonsteroidal synthetic estrogen. After menopause, when the body no longer produces estrogen, chlorotrianisene is used as a simple replacement of estrogen. The estrogen-stimulated endometrium may bleed within 48-72 hours after discontinuance of estrogen therapy. Paradoxically, prolonged estrogen therapy may cause shrinkage of the endometrium and an increase in size of the myometrium. Estrogens have a weak anabolic effect and may cause sodium retention with associated fluid retention and edema. Estrogens may also decrease elevated blood cholesterol and phospholipid concentrations. Estrogens affect bone by increasing calcium deposition and accelerating epiphyseal closure, following initial growth stimulation. During the preovulatory or nonovulatory phase of the menstrual cycle, estrogen is the principal determinant in the onset of menstruation. A decline of estrogenic activity at the end of the menstrual cycle also may induce menstruation; however, the cessation of progesterone secretion is the most important factor during the mature ovulatory phase of the menstrual cycle. The benefit derived from estrogen therapy in the prevention of postpartum breast engorgement must be carefully weighed against the potential increased risk of puerperal thromboembolism associated with the use of large doses of estrogens.
Merbentul for patients
Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.
A history of cancer of the breast or reproductive organs; a family history of breast cancer; breast lumps; heart or blood vessel disease; asthma; bone disease; gallbladder disease; liver or kidney problems; migraines; seizures; or phlebitis.
Additional information about Merbentul
Merbentul Indication: Used to treat symptoms of menopause, deficiencies in ovary function (including underdevelopment of female sexual characteristics and some types of infertility), and in rare cases, prostate cancer. Merbentul may also be used to prevent breast engorgement following childbirth.
Mechanism Of Action: Merbentul binds to the estrogen receptor on various estrogen receptor bearing cells. Target cells include cells in the female reproductive tract, the mammary gland, the hypothalamus, and the pituitary. Estrogens increase the hepatic synthesis of sex hormone binding globulin (SHBG), thyroid-binding globulin (TBG), and other serum proteins and suppress follicle-stimulating hormone (FSH) from the anterior pituitary.
Drug Interactions: Not Available
Food Interactions: Not Available
Generic Name: Chlorotrianisene
Synonyms: Chlorotrianisenum [Inn-Latin]; Chlorotrianisine; Chlorotrianizen; Chlortrianisen; Chlortrianisene; Chlortrianisenum; Chlortrianisestrol; Chlortrianisoestrolum; Clorotrianiseno [Inn-Spanish]; CTA; Chloortrianisestrol; Chlorestrolo; Chlortrianizen
Drug Category: Antineoplastic Agents; Estrogens, Non-Steroidal
Drug Type: Small Molecule; Approved
Absorption: Absorption following oral administration is rapid.
Toxicity (Overdose): Acute overdosage of large doses of oral contraceptives in chidren reportedly produces almost no toxicity except nausea and vomiting. Acute overdosage of estrogens may cause nausea, and withdrawal bleeding may occur in females.
Protein Binding: 50-80%
Biotransformation: Metabolized principally in the liver, although the kidneys, gonads, and muscle tissues may be involved to some extent. The metabolic fate of the synthetic estrogens has not been fully elucidated.
Half Life: Not Available
Dosage Forms of Merbentul: Capsule Oral
Chemical IUPAC Name: 1-[2-chloro-1,2-bis(4-methoxyphenyl)ethenyl]-4-methoxybenzene
Chemical Formula: C23H21ClO3
Chlorotrianisene on Wikipedia: https://en.wikipedia.org/wiki/Chlorotrianisene
Organisms Affected: Humans and other mammals